AtriCure (ATRC) Stock Price, News & Analysis

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings or view top-rated stocks.

7 equities research analysts have issued 12-month price targets for AtriCure's shares. Their ATRC share price targets range from $49.00 to $74.00. On average, they anticipate the company's share price to reach $60.13 in the next twelve months. This suggests a possible upside of 76.1% from the stock's current price.
View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts.

AtriCure's stock was trading at $44.38 at the beginning of 2023. Since then, ATRC shares have decreased by 23.1% and is now trading at $34.14.
View the best growth stocks for 2023 here.

AtriCure saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 1,620,000 shares, an increase of 18.2% from the October 31st total of 1,370,000 shares. Based on an average daily volume of 356,500 shares, the days-to-cover ratio is presently 4.5 days.
View AtriCure's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our ATRC earnings forecast.

AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings results on Wednesday, November, 1st. The medical device company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. The medical device company earned $98.29 million during the quarter, compared to analysts' expectations of $96.65 million. AtriCure had a negative net margin of 6.52% and a negative trailing twelve-month return on equity of 6.37%. The company's quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.27) EPS.

ETFs with the largest weight of AtriCure (NASDAQ:ATRC) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Nuveen Small Cap Select ETF (NSCS), Simplify Health Care ETF (PINK), Harbor Corporate Culture Small Cap ETF (HAPS), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI).

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT).

AtriCure's stock is owned by many different retail and institutional investors. Top institutional shareholders include Fred Alger Management LLC (3.03%), Wellington Management Group LLP (2.60%), Invesco Ltd. (2.18%), TimesSquare Capital Management LLC (1.91%), Loomis Sayles & Co. L P (1.82%) and Fiera Capital Corp (1.45%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends.

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.